Skip to main content
Ali Mirmiran, Mingyi Chen from Pathologist Connect Commented on a Post
  • Saved

Now that KRAS G12C mutations and other emerging biomarkers are actively being researched as potential therapeutic targets in NSCLC, how will this inform your approach to diagnostic testing and documentation of results? How do you record test results from diagnosis in the event that they become actionable later in a patient’s journey?

  • 19 hours 33 min
    I will now add KRAS testing to my reflex tests for metastatic NSCLC. All of the results of reflux tests are entered into our EMR (Cerner) for easy access to the information for purposes of appropriate therapeutic decision-making.
  • from Pathologist Connect 21 hours 40 min
    The in house test result will be automatically shown in EMR, the outside report lacks interface, but will be scanned as an addendum of pathology report.
  • from Pathologist Connect 23 hours 4 min
    In house testing will generate a report that flows from the pathology LIS to the EMR. Any outside testing, i.e. Foundation, Neogenomics, etc, in which there is no interface needs reports manually scanned into Epic. This presents some difficulty when looking for results, as they could be in multiple locations. There is a definite need for a central repository, not just within a health care system, but across systems. Anyone else have this issue?
  • 1 week 2 days
    KRAS G12 mutations usually have an unfavorable prognosis with no targeted therapy approved as yet. We can start with NGS at diagnosis to include extended panels incase if any get approved down the line. We currently have a phase I/II study with dose escalation of combination RMC-4630 and cobimetinib in relapsed refractory solid tumors with KRAS mutations. Other agents in study are AMG 510 and MRTX849
  • 1 week 3 days
    I do NGS on all pts which include G12C.i have now 2 pts with this mutation.A potential molecule AMG 510 is in clinical trial.
  • 1 week 3 days
    I usually perform NGS via liquid biopsy at diagnosis of metastatic disease, and now including the specific KRAS variant in my note. We also have an EMR repository of genomic information, which is also reviewed by some of our research team as needed.
  • 2 weeks 3 days
    Results of tumor genotyping for all metastatic NSCLC cases are readily accessible through our EMR.
  • 1 month 2 weeks
    Currently not clear KRAS Amplification is actional by down stream inhibitors like MEK or ERK
  • from Pathologist Connect 1 month 2 weeks
    depends on how effective is the potential therapy targeted to this mutation, it' side-effects/toxicity and cost. How much tissue, and quality of tissue (viz. time span from tissue processing as FFPE, from cytology slides etc), is required for the analysis. If ordered by pathologist, then reported as addendum to report. If requested by treating clinician, report from the testing lab sent to them with a copy retained in the lab.
  • 1 month 3 weeks
    Any suggestions about KRAS amplification